<DOC>
	<DOCNO>NCT02489500</DOCNO>
	<brief_summary>Standard treatment AL Amyloidosis high-dose melphalan stem cell transplant . This study compare safety effectiveness standard treatment high-dose melphalan stem cell transplant , compare investigational bortezomib use combination standard treatment high-dose melphalan stem cell transplant AL amyloidosis .</brief_summary>
	<brief_title>Trial HDM/SCT Versus HDM + Bortezomib/SCT AL Amyloidosis</brief_title>
	<detailed_description>This study seek enroll patient AL amyloidosis recommend standard treatment high-dose melphalan stem cell transplant . Standard treatment disease high-dose melphalan stem cell transplant . The purpose study compare safety effectiveness standard treatment high-dose melphalan stem cell transplant , compare investigational bortezomib use combination standard treatment high-dose melphalan stem cell transplant AL amyloidosis . Patients enrol study receive either standard treatment high-dose melphalan stem cell transplant , investigational bortezomib use combination standard treatment high-dose melphalan stem cell transplant .</detailed_description>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>1 . Histological diagnosis primary systemic ( AL ) amyloidosis base : Deposition amyloid material Congo red stain show characteristic apple green birefringence , AND… evidence clonal plasma cell dyscrasia monoclonal protein serum urine immunofixation electrophoresis study AND/OR abnormal serum free light chain assay AND/OR clonal plasma cell bone marrow exam demonstrate immunohistochemistry , flow cytometry situ hybridization AND… evidence organ involvement carpal tunnel syndrome . Patients senile , secondary , localize , dialysisrelated familial amyloidosis eligible . Confirmation tissue diagnosis sit organ dysfunction encourage , require . 2 . Patients must &gt; 18 year age . 3 . Patients must performance status 02 Eastern Cooperative Oncology Group ( ECOG ) criteria 4 . Patients must leave ventricular ejection fraction ( LVEF ) &gt; 45 % echocardiogram within 60 day enrollment 5 . Pulmonary Function Tests must show diffuse capacity lung carbon monoxide ( DLCO ) &gt; 50 % . 6 . All patient must inform investigational nature study must sign give write informed consent accordance institutional federal guideline . 1 . Patients recent ( &lt; 6 month ) myocardial infarction , congestive heart failure , New York Heart Association ( NYHA ) class III/IV arrhythmia refractory medical therapy ineligible . 2 . Prior chemotherapy alkylating agent allow evidence Myelodysplastic Dysplastic Syndrome ( MDS ) morphologically cytogenetically . Total cumulative dose oral melphalan must &lt; 300 mg . Patients receive cytotoxic therapy &lt; 4 week prior registration fully recovered effect therapy . 3 . Patients must overt multiple myeloma ( &gt; 30 % bone marrow plasmacytosis , extensive ( &gt; 2 ) lytic lesion hypercalcemia ) . 4 . No prior malignancy allow except follow : adequately treat basal cell squamous cell skin cancer , situ cervical cancer , adequately treated Stage I II cancer patient currently complete remission , cancer patient diseasefree 5 year . 5 . Patients must HIV positive . 6 . Pregnant nursing woman may participate . Women men reproductive potential may participate unless agree use effective contraceptive method .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>AL Amyloidosis</keyword>
	<keyword>Stem Cell Transplantation</keyword>
</DOC>